Hyperprogression after nivolumab for the treatment of melanoma
How to cite this article: Perea Polak A, Martínez García S, Godoy Díaz DJ. Hyperprogression after nivolumab for the treatment of melanoma. Indian J Dermatol Venereol Leprol, doi: 10.25259/IJDVL_160_2021
We report a 84-year-old man with stage IIIC melanoma: T3b, N0, M0 (American Joint Committee on Cancer, AJCC8) and BRAF +, who was treated with vemurafenib followed by nivolumab due to progressive cutaneous and subcutaneous disease [Figure 1]. The patient initially responded to our treatment, but after some months, he presented with disease hyperprogression infiltrating the entire thoracoabdominal wall [Figure 2] and finally succumbed to it.
Checkpoint inhibitors are effective therapeutic options for melanoma. However, a subset of patients presents with hyperprogressive disease on continuous use of anti-programmed cell death-1 agents, similar to our case.
Declaration of patient consent
The patient’s consent is not required as the patient’s identity is not disclosed or compromised.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.